---
title: "Trimethoprim suppresses phage activity and lowers toxin production in STEC, including with DNA‑dam"
id: "biorxiv-0-trimethoprim-suppress-phage-activity-and-reduces-toxin-production-in-a-clinical"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-0-trimethoprim-suppress-phage-activity-and-reduces-toxin-production-in-a-clinical"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.09.17.752489v1?rss=1"
published_at: "2026-09-22T08:47:28.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Trimethoprim suppresses phage activity and lowers toxin production in STEC, including with DNA‑dam
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-0-trimethoprim-suppress-phage-activity-and-reduces-toxin-production-in-a-clinical
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.09.17.752489v1?rss=1)
- **Published At:** 2026-09-22T08:47:28.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study examined how **trimethoprim** and acid exposure affect phage activity and Shiga toxin production in Shiga toxin–producing Escherichia coli (**STEC**). - Antibiotics that damage bacterial DNA typically increase phage induction and thereby raise toxin output, which is why antibiotics are usually contraindicated for STEC infections. - The authors report that both acid exposure and trimethoprim reduce phage production by roughly 100-fold, even when DNA‑damaging antibiotics are present. - These suppressive effects operate independently of the canonical bacterial **SOS** response normally implicated in phage induction. - Trimethoprim requires, at least in part, the bacterial glutamate‑dependent acid stress response to exert its phage‑suppressive action. - Mechanistically, trimethoprim permits early steps of phage induction but blocks phage genomic replication, preventing full phage production. - The authors translated the findings to a clinical STEC isolate and observed that trimethoprim markedly reduced Shiga toxin production, again despite co‑exposure to antibiotics that normally enhance phage activity. - The work suggests a potential therapeutic lead for treating STEC infections without provoking lethal increases in toxin, but it is reported as a preprint and has not been peer reviewed. - Funding sources reported include the Natural Sciences and Engineering Research Council and the Farncombe Family Chair in Phage Biology; authors declared no competing interests.
## Clinical Analysis & Structured Key Points
[](https://www.biorxiv.org/cdn-cgi/content?id=asm2VsTcfnJBvy1ZZzm8zr3OJqoHv5rAo0Nwvu70sN0-1790067007.0354564-1.2.1.1-ovKCfOfRKX1xhk2Vj32K3wMzBLR1mNow4NTc31i5lgrIer9luH0JoQ4lItEs1DyW) [Skip to main content](https://www.biorxiv.org/content/10.64898/2026.09.17.752489v1?rss=1#main-content) [![bioRxiv](https://www.biorxiv.org/sites/default/files/biorxiv_article_logo.jpg)](https://www.biorxiv.org/) * [Home](https://www.biorxiv.org/) * [Submit](https://www.biorxiv.org/submit-a-manuscript) * [FAQ](https://www.biorxiv.org/about/FAQ) * [Blog](https://connect.biorxiv.org/news/) * [ALERTS / RSS](https://www.biorxiv.org/content/alertsrss) * [Resources](https://connect.biorxiv.org/resources/) * [About](https://www.biorxiv.org/content/about-biorxiv) * [Channels](https://www.biorxiv.org/content/10.64898/2026.09.17.752489v1?rss=1) * [4D Nucleome](https://connect.biorxiv.org/relate/content/66) * [Academia Sinica](https://connect.biorxiv.org/group/content/38) * [Advances in Genome Biology and Technology (AGBT) General Meeting 2016 #AGBT16](https://connect.biorxiv.org/relate/content/10) * [Albert Einstein College of Medicine](https://connect.biorxiv.org/group/content/4) * [Aligning Science Across Parkinson's (ASAP)](https://connect.biorxiv.org/relate/content/195) * [Allen Institute for Cell Science](https://connect.biorxiv.org/relate/content/71) * [Arc Institute](https://connect.biorxiv.org/relate/content/224) * [Babraham Institute](https://connect.biorxiv.org/relate/content/197) * [BICCN/BICAN](https://connect.biorxiv.org/relate/content/208) * [BioImaging North America](https://connect.biorxiv.org/relate/content/194) * [Biology of Genomes 2016 #BOG16](https://connect.biorxiv.org/relate/content/19) * [Breakthrough Discoveries for Thriving with Bipolar Disorder](https://connect.biorxiv.org/relate/content/236) * [Brown University](https://connect.biorxiv.org/group/content/9) * [California Institute of Technology](https://connect.biorxiv.org/group/content/32) * [Carnegie Mellon University](https://connect.biorxiv.org/group/content/19) * [Case Western Reserve University](https://connect.biorxiv.org/group/content/36) * [Central Oxford Structural Microscopy and Imaging](https://connect.biorxiv.org/relate/content/143) * [Centre for Microbiology and Environmental Systems Science](https://connect.biorxiv.org/relate/content/190) * [Chan Zuckerberg Biohub](https://connect.biorxiv.org/relate/content/121) * [Columbia University](https://connect.biorxiv.org/group/content/27) * [Donders Institute for Brain, Cognition and Behaviour](https://connect.biorxiv.org/relate/content/184) * [DREAM](https://connect.biorxiv.org/relate/content/153) * [Drug Development and Clinical Therapeutics](https://connect.biorxiv.org/relate/content/52) * [ENCODE](https://connect.biorxiv.org/relate/content/177) * [Ernst Strüngmann Institute (ESI) for Neuroscience](https://connect.biorxiv.org/relate/content/211) * [European Molecular Biology Laboratory (EMBL)](https://connect.biorxiv.org/relate/content/159) * [Francis Crick Institute](https://connect.biorxiv.org/relate/content/88) * [Fred Hutchinson Cancer Center](https://connect.biorxiv.org/group/content/28) * [Georgia Institute of Technology](https://connect.biorxiv.org/group/content/20) * [Harvard Program in Therapeutic Sciences](https://connect.biorxiv.org/relate/content/151) * [The Howard Hughes Medical Institute (HHMI)](https://connect.biorxiv.org/relate/content/227) * [Human Cell Atlas](https://connect.biorxiv.org/relate/content/163) * [Human Pangenome Reference Consortium (HPRC)](https://connect.biorxiv.org/relate/content/215) * [IMO Workshop](https://connect.biorxiv.org/relate/content/8) * [Impact of Genomic Variation on Function (IGVF)](https://connect.biorxiv.org/relate/content/214) * [Institut Pasteur](https://connect.biorxiv.org/relate/content/235/channel) * [Institute of Science and Technology Austria](https://connect.biorxiv.org/group/content/12) * [International Human Epigenome Consortium (IHEC)](https://connect.biorxiv.org/relate/content/219) * [International Mouse Phenotyping Consortium (IMPC)](https://connect.biorxiv.org/relate/content/185) * [Iowa State University](https://connect.biorxiv.org/group/content/6) * [Johns Hopkins University](https://connect.biorxiv.org/group/content/47) * [Mathematical Oncology](https://connect.biorxiv.org/relate/content/1) * [Micron Oxford](https://connect.biorxiv.org/relate/content/116) * [Michigan State University](https://connect.biorxiv.org/group/content/7) * [Morgridge Institute](https://connect.biorxiv.org/group/content/57) * [National Taiwan University](https://connect.biorxiv.org/group/content/39) * [NCI Cancer Systems Biology Consortium](https://connect.biorxiv.org/relate/content/210) * [NF Open Science Initiative](https://connect.biorxiv.org/relate/content/213) * [NCI Human Tumor Atlas Network](https://connect.biorxiv.org/relate/content/171) * [Neuromatch Conference](https://connect.biorxiv.org/relate/content/209) * [NeurotechEU](https://connect.biorxiv.org/relate/content/189) * [North Carolina State University](https://connect.biorxiv.org/group/content/37) * [Northeastern University](https://connect.biorxiv.org/group/content/54) * [Oregon Health & Sciences University](https://connect.biorxiv.org/group/content/22) * [RNA Therapeutics Institute at UMass Chan Med School](https://connect.biorxiv.org/relate/content/243) * [Rosetta Commons](https://connect.biorxiv.org/relate/content/191) * [Rutgers University](https://connect.biorxiv.org/group/content/31) * [SeroNet](https://connect.biorxiv.org/relate/content/192) * [Simons Foundation Autism Research Initiative (SFARI)](https://connect.biorxiv.org/relate/content/74) * [Society for Molecular Biology and Evolution #SMBE2016](https://connect.biorxiv.org/relate/content/29) * [Somatic Cell Genome Editing Program](https://connect.biorxiv.org/relate/content/167) * [Somatic Mosaicism across the Human Tissues Network](https://connect.biorxiv.org/relate/content/222) * [SPARC](https://connect.biorxiv.org/relate/content/187) * [Stowers Institute for Medical Research](https://connect.biorxiv.org/group/content/3) * [Stockholm University](https://connect.biorxiv.org/group/content/14) * [Tel Aviv University](https://connect.biorxiv.org/group/content/8) * [The Michael J. Fox Foundation](https://connect.biorxiv.org/relate/content/207) * [The Rockefeller University](https://connect.biorxiv.org/group/content/2) * [The Sainsbury Laboratory](https://connect.biorxiv.org/relate/content/98) * [The Whitehead Institute](https://connect.biorxiv.org/relate/content/212) * [University of Connecticut Health Center](https://connect.biorxiv.org/group/content/16) * [University of California, Berkeley](https://connect.biorxiv.org/group/content/13) * [University of California, San Diego](https://connect.biorxiv.org/group/content/41) * [University of California, San Francisco](https://connect.biorxiv.org/group/content/10) * [University of Chicago](https://connect.biorxiv.org/group/content/42) * [University of Geneva](https://connect.biorxiv.org/group/content/26) * [University of Guelph](https://connect.biorxiv.org/group/content/23) * [University of Hong Kong](https://connect.biorxiv.org/group/content/29) * [University of Illinois Chicago](https://connect.biorxiv.org/group/content/43) * [University of Iowa](https://connect.biorxiv.org/group/content/24) * [University of Kansas](https://connect.biorxiv.org/group/content/33) * [University of Massachusetts Chan Medical School](https://connect.biorxiv.org/group/content/44) * [University of New South Wales](https://connect.biorxiv.org/group/content/25) * [University of Ottawa](https://connect.biorxiv.org/group/content/35) * [University of Sydney](https://connect.biorxiv.org/group/content/50) * [Vanderbilt University](https://connect.biorxiv.org/group/content/30) * [Vienna BioCenter](https://connect.biorxiv.org/relate/content/186) * [Washington University in St. Louis](https://connect.biorxiv.org/group/content/11) * [Weizmann Institute of Science](https://connect.biorxiv.org/group/content/15) * [Yale University](https://connect.biorxiv.org/group/content/53) Search for this keyword [Advanced Search](https://www.biorxiv.org/search) New Results Follow this preprint # Trimethoprim suppress phage activity and reduces toxin production in a clinical STEC strain, even in the presence of DNA-damaging antibiotics [ View ORCID Profile](http://orcid.org/0009-0008-7739-3072)Ayesha Umair, [ View ORCID Profile](http://orcid.org/0000-0002-7058-6006)Alexander P Hynes doi: https://doi.org/10.64898/2026.09.17.752489 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Ayesha Umair McMaster University * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ayesha%2BUmair%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Umair%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AAyesha%2BUmair%2B) * [ORCID record for Ayesha Umair](http://orcid.org/0009-0008-7739-3072 "Open in new tab") Alexander P Hynes McMaster University * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Alexander%2BP%2BHynes%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Hynes%20AP&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AAlexander%2BP%2BHynes%2B) * [ORCID record for Alexander P Hynes](http://orcid.org/0000-0002-7058-6006 "Open in new tab") * For correspondence: hynes@mcmaster.ca * [Abstract](https://www.biorxiv.org/content/10.64898/2026.09.17.752489v1)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_art/node:5799455/1) * [Info/History](https://www.biorxiv.org/content/10.64898/2026.09.17.752489v1.article-info)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_info/node:5799455/1) * [Metrics](https://www.biorxiv.org/content/10.64898/2026.09.17.752489v1.article-metrics)[](https://www.biorxiv.org/panels_ajax_tab/article_tab_metrics/node:5799455/1) * [ Preview PDF](https://www.biorxiv.org/content/10.64898/2026.09.17.752489v1.full.pdf+html)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:5799455/1) ![Loading](https://www.biorxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Shiga toxin-producing _Escherichia coli_ (STEC) are virulent due to their production of lethal toxins, which are genetically encoded by viruses that exclusively infect these bacteria, called phages. After infection, children and immunocompromised patients are particularly at risk of developing life-threatening complications. Antibiotics are contraindicated here, because they increase phage activity, and this leads to increased toxin production. This limits treatments to fluid resuscitation and supportive care. Here, we describe how acid exposure and trimethoprim both potently suppress phage production ~100-fold, even in the presence of antibiotics that increase phage activity. We characterized these stimuli further, and found that they suppress phages independently of canonical bacterial SOS responses that are well-established to be involved in phage activity. Trimethoprim partially relies on the glutamate-dependent bacterial acid stress response to have this suppressive effect. It allows the earliest steps of phage induction to happen, but completely blocks their genomic replication. We translated these findings to a clinical STEC isolate and found that trimethoprim potently suppressed toxin production, again, even in the presence of antibiotics that increase phage activity. These findings form a key lead in finding a new option to treat these infections, without risking potentially lethal complications. ### Competing Interest Statement The authors have declared no competing interest. ## Funder Information Declared Natural Sciences and Engineering Research Council, https://ror.org/01h531d29, 2026-07094 Farncombe Family Chair in Phage Biology Natural Sciences and Engineering Research Council, https://ror.org/01h531d29, CGS-M Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.biorxiv.org/content/10.64898/2026.09.17.752489v1?rss=1#page) [ Previous](https://www.biorxiv.org/content/10.1101/2024.08.30.610360v3 "Distinct phenotypic consequences of cholangiocarcinoma-associated FGFR2 alterations depend on biliary epithelial cell state")[Next ](https://www.biorxiv.org/content/10.64898/2026.03.24.713852v2 "Developmental variation in pterygoid segmentation clarifies patterns of avian bony palate evolution") Posted September 22, 2026. [ Download PDF](https://www.biorxiv.org/content/10.64898/2026.09.17.752489v1.full.pdf) Print/Save Options [Download PDF](https://www.biorxiv.org/content/biorxiv/early/2026/09/22/2026.09.17.752489.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.biorxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Email](https://www.biorxiv.org/ "Email this Article") [ Share](https://www.biorxiv.org/) Trimethoprim suppress phage activity and reduces toxin production in a clinical STEC strain, even in the presence of DNA-damaging antibiotics Ayesha Umair, Alexander P Hynes bioRxiv 2026.09.17.752489; doi: https://doi.org/10.64898/2026.09.17.752489 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Share This Article: Copy [![Twitter logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.biorxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.09.17.752489v1%26text%3DTrimethoprim%2520suppress%2520phage%2520activity%2520and%2520reduces%2520toxin%2520production%2520in%2520a%2520clinical%2520STEC%2520strain%252C%2520even%2520in%2520the%2520presence%2520of%2520DNA-damaging%2520antibiotics "Share this on Twitter") [![Facebook logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.biorxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.09.17.752489v1%26t%3DTrimethoprim%2520suppress%2520phage%2520activity%2520and%2520reduces%2520toxin%2520production%2520in%2520a%2520clinical%2520STEC%2520strain%252C%2520even%2520in%2520the%2520presence%2520of%2520DNA-damaging%2520antibiotics "Share on Facebook") [![LinkedIn logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.biorxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.09.17.752489v1%26title%3DTrimethoprim%2520suppress%2520phage%2520activity%2520and%2520reduces%2520toxin%2520production%2520in%2520a%2520clinical%2520STEC%2520strain%252C%2520even%2520in%2520the%2520presence%2520of%2520DNA-damaging%2520antibiotics%26summary%3D%26source%3DbioRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.biorxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.09.17.752489v1%26title%3DTrimethoprim%2520suppress%2520phage%2520activity%2520and%2520reduces%2520toxin%2520production%2520in%2520a%2520clinical%2520STEC%2520strain%252C%2520even%2520in%2520the%2520presence%2520of%2520DNA-damaging%2520antibiotics "Share on Mendeley") [ Citation Tools](https://www.biorxiv.org/ "Citation Tools") [ Get QR code](https://connect.biorxiv.org/qr/2026.09.17.752489) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.biorxiv.org/content/10.64898/2026.09.17.752489v1&count=horizontal&via=&text=Trimethoprim%20suppress%20phage%20activity%20and%20reduces%20toxin%20production%20in%20a%20clinical%20STEC%20strain%2C%20even%20in%20the%20presence%20of%20DNA-damaging%20antibiotics&counturl=www.biorxiv.org/content/10.64898/2026.09.17.752489v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.biorxiv.org/content/early/recent) * [Animal Behavior and Cognition](https://www.biorxiv.org/collection/animal-behavior-and-cognition) (8019) * [Biochemistry](https://www.biorxiv.org/collection/biochemistry) (18745) * [Bioengineering](https://www.biorxiv.org/collection/bioengineering) (14895) * [Bioinformatics](https://www.biorxiv.org/collection/bioinformatics) (44470) * [Biophysics](https://www.biorxiv.org/collection/biophysics) (22614) * [Cancer Biology](https://www.biorxiv.org/collection/cancer-biology) (19729) * [Cell Biology](https://www.biorxiv.org/collection/cell-biology) (26908) * [Clinical Trials](https://www.biorxiv.org/collection/clinical-trials) (138) * [Developmental Biology](https://www.biorxiv.org/collection/developmental-biology) (13972) * [Ecology](https://www.biorxiv.org/collection/ecology) (21010) * [Epidemiology](https://www.biorxiv.org/collection/epidemiology) (2067) * [Evolutionary Biology](https://www.biorxiv.org/collection/evolutionary-biology) (25462) * [Genetics](https://www.biorxiv.org/collection/genetics) (16176) * [Genomics](https://www.biorxiv.org/collection/genomics) (23526) * [Immunology](https://www.biorxiv.org/collection/immunology) (18718) * [Microbiology](https://www.biorxiv.org/collection/microbiology) (42539) * [Molecular Biology](https://www.biorxiv.org/collection/molecular-biology) (18066) * [Neuroscience](https://www.biorxiv.org/collection/neuroscience) (93547) * [Paleontology](https://www.biorxiv.org/collection/paleontology) (700) * [Pathology](https://www.biorxiv.org/collection/pathology) (2984) * [Pharmacology and Toxicology](https://www.biorxiv.org/collection/pharmacology-and-toxicology) (5102) * [Physiology](https://www.biorxiv.org/collection/physiology) (8122) * [Plant Biology](https://www.biorxiv.org/collection/plant-biology) (16000) * [Scientific Communication and Education](https://www.biorxiv.org/collection/scientific-communication-and-education) (2095) * [Synthetic Biology](https://www.biorxiv.org/collection/synthetic-biology) (4562) * [Systems Biology](https://www.biorxiv.org/collection/systems-biology) (10237) * [Zoology](https://www.biorxiv.org/co
## Related Clinical Research

- [Prolonged SARS-CoV-2 Infections and Delayed Immunity Promote Transmission of Mutated Variants](https://medichelpline.com/clinical-feed/biorxiv-0-transmission-of-mutated-sars-cov-2-variants-is-favored-by-relatively-prolonged.md)
- [pH-dependent protein kinase cascade controls Leishmania differentiation in the sand fly](https://medichelpline.com/clinical-feed/biorxiv-0-a-ph-dependent-protein-kinase-cascade-regulates-divergent-differentiation-of.md)
- [Fokker-Planck Optimal Control Framework for Stochastic Epidemic Models](https://medichelpline.com/clinical-feed/pubmed-42747468.md) (DOI: 10.1007/s00285-026-02462-7)
- [Neurocysticercosis in California: Prevalence, Demographics, and Neuropsychiatric Comorbidities in](https://medichelpline.com/clinical-feed/medrxiv-0-neurocysticercosis-in-california-clinical-characteristics-and-associated.md)
- [Anas barbariae 200K (Oscillococcinum) for influenza-like illness: randomized double-blind multicen](https://medichelpline.com/clinical-feed/medrxiv-1-efficacy-and-safety-of-anas-barbariae-200k-in-influenza-like-illness-a.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.